Fairvalue-Calculator Fairvalue-Calculator
EN DE

ZGOO Holdings (221800) Fair Value & Analysis

Healthcare · KR · Market cap 137B KRW

Price6,350 KRW
Fair Value7,777 KRW
Upside+22.5%
Quality95/100
Evidence: Low Range 5,833 KRW – 9,721 KRW

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

ZGOO Holdings (221800) currently trades at 6,350 KRW, while our model-based Fair Value estimate is 7,777 KRW — implying the stock looks roughly 22.5% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

ZGOO Holdings Co., Ltd. provides healthcare services in South Korea. The company also offers specimen testing services; digital healthcare services related to testing and health examinations; and bio-technology platforms. The company was formerly known as U2Bio Co., Ltd. and changed its name to ZGOO Holdings Co., Ltd. in April 2026. The company was founded in 2009 and is headquartered in Seoul, South Korea.

Open the full interactive analysis →

Similar stocks

Thermo Fisher Scientific Inc (TMO) -34% Danaher Corporation (DHR) -37% WuXi AppTec Co (WUXAY) +35% IDEXX Laboratories, Inc (IDXX) -54% Lonza Group (LZAGY) -59% Agilent Technologies, Inc (A) -50%

Frequently asked questions

Is ZGOO Holdings (221800) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 7,777 KRW versus a price of 6,350 KRW — about +22% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 221800?
Our 21-model fair value for ZGOO Holdings is 7,777 KRW (as of Jun 24, 2026), built from audited fundamentals. The current price is 6,350 KRW.
What is the quality score of 221800?
ZGOO Holdings has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.